ONO-4538 Multicenter, Open-label, Uncontrolled, Phase II Study in Advanced Non-small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 18 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2014 New trial record